A B S T R A C T

Background
Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil.
Objectives
The objective of this review was to assess the effects of Nicobrevin on long term smoking cessation
Search strategy
We searched the Cochrane Tobacco Addiction Group trials register. Most recent search was January 2009.
Selection criteria
Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up.
Data collection and analysis
Data were sought on the outcome, method of randomization, and completeness of follow up.
Main results
We identified no trials meeting the full inclusion criteria including long-term follow up.
Authors' conclusions
There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.
P L A I N L A N G U A G E S U M M A R Y
Does nicobrevin help people to stop smoking
Nicobrevin is a proprietary product containing quinine, menthyl valerate, camphor and eucalyptus oil marketed as an aid to smoking cessation. No randomized trials with long term follow up of smoking status were identified, so there was no evidence to assess efficacy.
B A C K G R O U N D
A range of products are marketed to smokers trying to quit. There is good evidence that some products can increase the chance of a successful quit attempt, by reducing the urge to smoke or reducing the feelings of craving and withdrawal. Effective products include all forms of nicotine replacement therapy, and some antidepressant pharmacotherapies. Other products such as those containing silver acetate, or lobeline, have not been shown to be effective in high quality clinical trials. A large number of proprietary remedies are marketed to smokers even though they do not contain ingredients established to be effective. A list of such products, with detailed information on each, is maintained by the Campaign for TobaccoFree Kids (TobaccoFreeKids 2005).
Nicobrevin is marketed as a smoking cessation aid in 11 countries including the UK, New Zealand and Germany. The formulation marketed in the UK contains four 'active' ingredients; quinine 15mg, menthyl valerate 100mg, camphor 10mg and eucalyptus oil 10mg (Nicobrevin 2006) . The manufacturers claim that quinine may reduce craving, camphor and eucalyptus can relieve respiratory congestion and gastrointestinal disturbance and menthyl valerate has a sedative effect.
O B J E C T I V E S
To assess the evidence for the effectiveness of Nicobrevin in assisting long-term smoking cessation.
The hypothesis tested was that Nicobrevin was more effective than placebo, or an alternative treatment, in achieving long-term smoking cessation.
M E T H O D S Criteria for considering studies for this review Types of studies
Randomized studies using a placebo or an alternative therapeutic control.
Types of participants
Smokers wishing to quit.
Types of interventions
Treatment with Nicobrevin (a 28-day course of tablets).
Types of outcome measures
Smoking cessation, assessed at follow up at least six months from the start of treatment, following the recommendations of the Russell Standard (West 2005).
Search methods for identification of studies
We searched the Tobacco Addiction Review Group specialised register for trials, using the term 'Nicobrevin' in the title, abstract or keyword. This register has been developed from electronic searching of databases including MEDLINE, EMBASE, PsycINFO and Web of Science, together with hand searching of specialist journals, conference proceedings and reference lists of previous trials and overviews. We also made contact with the English Department of Health to obtain data submitted for the product licensing of Nicobrevin in the UK. Our most recent electronic search for 'Nicobrevin' in title, abstract or keyword was January 2009.
Data collection and analysis
Trials using a relevant intervention were identified by one author and checked by a second. For trials meeting the inclusion criteria the number of quitters at the longest follow up would be extracted. Quitting would be based on the strictest available criteria to define cessation, using sustained abstinence in preference to point prevalence if both were presented. In studies which used biochemical validation of cessation, only those subjects meeting the criteria for biochemically confirmed abstinence would be regarded as having stopped smoking. Participants in any group lost to follow up would be regarded as being continuing smokers. Data would be extracted by one reviewer and checked by a second. In the event of there being more than one eligible trial, meta-analysis would be used to derive a typical odds ratio and its associated confidence intervals, using the Mantel-Haenszel method and a fixed-effect model.
R E S U L T S Description of studies
See: Characteristics of excluded studies. We found no studies meeting all the inclusion criteria. Only two trials of Nicobrevin have been published and neither had long term follow up. One assessed patients at the end of four weeks treatment (Dankwa 1988 ) and the other after three months (Schmidt 1974) .
Risk of bias in included studies
Lack of long-term follow up was a reason for exclusion of both known trials.
Effects of interventions
Due to the lack of trials there is no evidence to support an effect of Nicobrevin on long-term cessation.
D I S C U S S I O N
There are many smoking cessation remedies available which have been not subjected to the same process of clinical testing as those pharmacological cessation aids for which effectiveness is well established. Nicobrevin includes active pharmaceutical ingredients, but none of these has been tested independently for an effect on smoking cessation and there is no strong rationale to believe that they have a specific effect on overcoming nicotine addiction. At best their respiratory and digestive system effects are most likely to relieve some of symptoms that smokers experience whilst abstaining from cigarettes. At the doses used they are unlikely to cause harm.
If trials with short-term outcomes had been included, both the identified trials would have had some methodological concerns. Dankwa 1988 was unusual in that the smokers were not asked to try to quit, and numbers of cigarettes smoked on the last day of therapy was the primary outcome. Levels of blood carbon monoxide were measured, but not related to smoking status so could not be used to validate self-reported quitting.
In the second study (Schmidt 1974) a variety of smoking cessation products were tested in a single trial. Participants received their allocated therapy by post. The placebo group received a placebo matched to the characteristics of another active therapy rather than to Nicobrevin, and there was no validation of self-reported quit rates.
It has been argued that requiring evidence of efficacy after longterm follow up is unnecessary to assess whether a product is of benefit, since smoking is a chronic condition and repeated quit attempts are generally needed. However since the benefits of quitting are only likely to come from sustained cessation, products that have not been shown to increase long-term quit rates cannot be recommended. It is possible that relapse rates may be relatively higher in actively treated groups after the end of treatment, so that the net benefit of treatment is eroded.
A U T H O R S ' C O N C L U S I O N S Implications for practice
We found insufficient clinical evidence for the effectiveness of Nicobrevin as an aid to sustained smoking cessation.
Implications for research
Well-designed randomized controlled trials with long-term follow up could test the effectiveness of Nicobrevin as a non-nicotinic aid to smoking cessation.
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